Patients participated in the TEAM trial, a prospective randomized study investigating tamoxifen versus exemestane as adjuvant therapy for hormone sensitive breast cancer
nolvadex Monitor women who received KADCYLA during pregnancy or within 7 months prior to conception for oligohydramnios